Apr, 2019 - Mar, 2021
Effects of novel anti-ASCT2 monoclonal antibody on human tumor harboring KRAS mutation
Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists
- Grant number
- 19K16876
- Japan Grant Number (JGN)
- JP19K16876
- Authorship
- Principal investigator
- Grant amount
-
- (Total)
- 4,290,000 Japanese Yen
- (Direct funding)
- 3,300,000 Japanese Yen
- (Indirect funding)
- 990,000 Japanese Yen
Mutations in KRAS are detected in various human cancers. However, there are few effective drugs for KRAS-mutated cancers. Glutamine is thought to be one of the pivotal nutrients for proliferation and survival of cancer cells. ASCT2 (SLC1A5) is a multi-pass transmembrane protein that transports neutral amino acids. ASCT2 is reported to be highly expressed in many cancer cells, and is thought to work as a major transporter for glutamine. We have developed a novel monoclonal antibody (mAb) against the extracellular domain of human ASCT2. In the present study, we examined the effects of the mAb on KRAS-mutated colorectal cancer cells. Treatment with anti-ASCT2 mAb decreased the concentration of intracellular glutamine and in vivo tumor growth. However, these effects were not observed in colorectal cancer cells which harbor wild-type KRAS. These results suggest that ASCT2 is a promising therapeutic target for KRAS-mutated cancers.
- Link information
- ID information
-
- Grant number : 19K16876
- Japan Grant Number (JGN) : JP19K16876